Global AI-Enabled Drug Discovery and Clinical Trials Market Insights, Size and Growth Forecast To 2027

Global AI-Enabled Drug Discovery and Clinical Trials Market by Component (Solutions and Services), By Solution (Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, Biomarker Research and Others), By Therapeutic Applications (Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Disorder, Metabolic Diseases, Immunologic Diseases, Infectious Diseases and Others), By End-User(Biopharmaceutical Industry, Contract Research Organizations (CROs), and Academic Institutes and Research Centers), and By Region (North America, Europe, Asia Pacific, South America, and Middle East & Africa), Forecast to 2020 to 2027

Published: Apr-2020	Report ID: HLCA2022	Pages: 1 - 250	Formats^*:
Category : Healthcare

Global AI-Enabled Drug Discovery and Clinical Trials market predicted to propel by the application of AI which improves the speed and precision of discovery and reduce timelines for drug discovery. Global AI-Enabled Drug Discovery and Clinical Trials market estimated to grow with a noteworthy rate during the forecast period, 2020-2027. It is due to AI helping companies in calculating vast patient datasets into digestible, tangible information, identifying personalized, precision medicine opportunities, or potential forecasting responses to new drugs. Additionally, the growing applications of AI to analyze the pool of potential subjects in drug discovery, analyzing the electronic medical reports of patients, and genomic data for improved clinical trial matching will contribute to the growth of AI-enabled drug discovery and clinical trials market. Moreover, the surge in the application of AI in drug discovery benefits from the open-source implementation will augment the global AI-enabled drug discovery and clinical trial market in the future time.

AI help in accelerating the treatments of rare diseases, identify potential rare diseases indications and predicts new indications for existing medicines. Further, growing adoption of Ai in the pharmacy industry for target discovery, compound synthesis, compound screening, crystal form prediction, patient recruitment, optimization of clinical trial design, and drug redirection will boom the AI-enabled drug discovery and clinical trials in the near future.

Components Overview in the Global AI-Enabled Drug Discovery and Clinical Trials Market

Based on components, the global AI-enabled drug discovery and clinical Trials market bifurcated into Solutions and Services. The Solutions segment likely to lead the market by 2027, attributable to AI, help in substantial implications in the development of biomarkers and detect the differences between healthy and cancerous tissues.

Solution Overview in the Global AI-Enabled Drug Discovery and Clinical Trials market

Based on the Solution, the global AI-Enabled drug discovery and clinical trials market classified into Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, Biomarker Research, and Others. The Drug Design segment estimated to gain a higher market share by 2017. It is due to AI, and Machine learning helps to discover and develop new drugs for chronic kidney disease and idiopathic pulmonary fibrosis.

Application Overview in the Global AI-Enabled Drug Discovery and Clinical Trials Market

Based on application, the global AI-Enabled Drug Discovery and Clinical Trials market classified into Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Disorder, Metabolic Diseases Immunologic Diseases, Infectious Diseases, and Others. The Oncology segment projected to register a higher CAGR by 2027, on account of the surge in demand for AI for improving the quality of care and patient outcomes and improve the accuracy of cancer diseases while minimizing damage to healthy organs at risk.

End-User Overview in the Global AI-Enabled Drug Discovery and Clinical Trials Market

Based on end-user, the global AI-enabled drug discovery and clinical trials market categorized into Biopharmaceutical Industry, Contract Research Organizations (CROs), and Academic Institutes and Research Centers. Biopharmaceutical Industry projected to lead the market by 2027, as a result of AI and machine learning help in manufacturing process improvement, identifying novel biological target, processing biomedical and clinical data, and detect diseases such as cancer.

Regional Overview in the Global AI-Enabled Drug Discovery and Clinical Trials Market

By geography, the Global AI-Enabled Drug Discovery and Clinical Trials Market segmented into North America, Asia Pacific, Europe, Middle East & Africa, and South America. North America accounted for a major share in 2019 and expected to dominate the market by 2027 the market as a result of the high focus on R&D & substantial investment in the healthcare sector by USA governments and the presence of globally leading pharmaceutical companies.

Global AI-Enabled Drug Discovery and Clinical Trials Market: Competitive Landscape

Companies such as Accutar Biotechnology Inc., AiCure, LLC, Ardigen, Atomwise, Inc, BenevolentAI, Berg LLC, Berkeley Lights, Inc., Biovista Inc, BioAge Labs, Inc., C4X Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., Cyclica, Inc., CytoReason, and Symphony Innovation, LLC are the key players in the Global AI-Enabled Drug Discovery and Clinical Trials Market.

1. Research Strategic Development

1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation

2. Research Methodology

2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation

3. Executive Summary

4. Market Insights

4.1. Economic Factor Analysis
4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges
4.2. Technological Landscape
4.3. Competitors & Product Analysis
4.4. Regulatory Framework
4.5. Company market share analysis, 2019
4.6. Porterâ€™s Five forces analysis
4.7. New Investment Analysis
4.8. PESTEL Analysis

5. Global AI-Enabled Drug Discovery and Clinical Trials Market Overview

5.1. Market Size & Forecast, 2016-2027
5.1.1. Demand
5.1.1.1. By Value (USD Million)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Component
5.2.1.1. Solutions
5.2.1.2. Services
5.2.2. By Solution
5.2.2.1. Data Aggregation and Analysis
5.2.2.2. Clinical Trials
5.2.2.3. Drug Design
5.2.2.4. Drug Characterization
5.2.2.5. Biomarker Research
5.2.2.6. Others
5.2.3. By Application
5.2.3.1. Oncology
5.2.3.2. Cardiovascular Diseases
5.2.3.3. Nervous System Diseases
5.2.3.4. Respiratory Disorder
5.2.3.5. Metabolic Diseases
5.2.3.6. Immunologic Diseases
5.2.3.7. Infectious Diseases
5.2.3.8. Others
5.2.4. By End-User
5.2.4.1. Biopharmaceutical Industry
5.2.4.2. Contract Research Organizations (CROs)
5.2.4.3. Academic Institutes and Research Centers
5.2.5. By Region
5.2.5.1. North America
5.2.5.2. Europe
5.2.5.3. Asia Pacific
5.2.5.4. South America
5.2.5.5. Middle East & Africa

6. North America AI-Enabled Drug Discovery and Clinical Trials Market Overview

6.1. North America AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
6.1.1. Demand
6.1.1.1. By Value (USD Million)
6.2. North America AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
6.2.1. By Component
6.2.1.1. Solutions
6.2.1.2. Services
6.2.2. By Solution
6.2.2.1. Data Aggregation and Analysis
6.2.2.2. Clinical Trials
6.2.2.3. Drug Design
6.2.2.4. Drug Characterization
6.2.2.5. Biomarker Research
6.2.2.6. Others
6.2.3. By Application
6.2.3.1. Oncology
6.2.3.2. Cardiovascular Diseases
6.2.3.3. Nervous System Diseases
6.2.3.4. Respiratory Disorder
6.2.3.5. Metabolic Diseases
6.2.3.6. Immunologic Diseases
6.2.3.7. Infectious Diseases
6.2.3.8. Others
6.2.4. By End-User
6.2.4.1. Biopharmaceutical Industry
6.2.4.2. Contract Research Organizations (CROs)
6.2.4.3. Academic Institutes and Research Centers
6.2.5. By Country
6.2.5.1. US
6.2.5.2. Canada
6.2.5.3. Mexico
6.2.6. Company Market Share (Top 3-5)
6.2.7. Economic Impact Study on North America AI-Enabled Drug Discovery and Clinical Trials Market

7. Europe AI-Enabled Drug Discovery and Clinical Trials Market Overview

7.1. Europe AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
7.1.1. Demand
7.1.1.1. By Value (USD Million)
7.2. Europe AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
7.2.1. By Component
7.2.1.1. Solutions
7.2.1.2. Services
7.2.2. By Solution
7.2.2.1. Data Aggregation and Analysis
7.2.2.2. Clinical Trials
7.2.2.3. Drug Design
7.2.2.4. Drug Characterization
7.2.2.5. Biomarker Research
7.2.2.6. Others
7.2.3. By Application
7.2.3.1. Oncology
7.2.3.2. Cardiovascular Diseases
7.2.3.3. Nervous System Diseases
7.2.3.4. Respiratory Disorder
7.2.3.5. Metabolic Diseases
7.2.3.6. Immunologic Diseases
7.2.3.7. Infectious Diseases
7.2.3.8. Others
7.2.4. By End-User
7.2.4.1. Biopharmaceutical Industry
7.2.4.2. Contract Research Organizations (CROs)
7.2.4.3. Academic Institutes and Research Centers
7.2.5. By Country
7.2.5.1. Germany
7.2.5.2. UK
7.2.5.3. France
7.2.5.4. Italy
7.2.5.5. Rest of Europe
7.2.6. Company Market Share (Top 3-5)
7.2.7. Economic Impact Study on Europe AI-Enabled Drug Discovery and Clinical Trials Market

8. Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market Overview

8.1. Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
8.1.1. Demand
8.1.1.1. By Value (USD Million)
8.2. Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
8.2.1. By Component
8.2.1.1. Solutions
8.2.1.2. Services
8.2.2. By Solution
8.2.2.1. Data Aggregation and Analysis
8.2.2.2. Clinical Trials
8.2.2.3. Drug Design
8.2.2.4. Drug Characterization
8.2.2.5. Biomarker Research
8.2.2.6. Others
8.2.3. By Application
8.2.3.1. Oncology
8.2.3.2. Cardiovascular Diseases
8.2.3.3. Nervous System Diseases
8.2.3.4. Respiratory Disorder
8.2.3.5. Metabolic Diseases
8.2.3.6. Immunologic Diseases
8.2.3.7. Infectious Diseases
8.2.3.8. Others
8.2.4. By End-User
8.2.4.1. Biopharmaceutical Industry
8.2.4.2. Contract Research Organizations (CROs)
8.2.4.3. Academic Institutes and Research Centers
8.2.5. By Country
8.2.5.1. China
8.2.5.2. India
8.2.5.3. Japan
8.2.5.4. Australia
8.2.5.5. Rest of Asia Pacific
8.2.6. Company Market Share (Top 3-5)
8.2.7. Economic Impact Study on Asia Pacific AI-Enabled Drug Discovery and Clinical Trials Market

9. South America AI-Enabled Drug Discovery and Clinical Trials Market Overview

9.1. South America AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
9.1.1. Demand
9.1.1.1. By Value (USD Million)
9.2. South America AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
9.2.1. By Component
9.2.1.1. Solutions
9.2.1.2. Services
9.2.2. By Solution
9.2.2.1. Data Aggregation and Analysis
9.2.2.2. Clinical Trials
9.2.2.3. Drug Design
9.2.2.4. Drug Characterization
9.2.2.5. Biomarker Research
9.2.2.6. Others
9.2.3. By Application
9.2.3.1. Oncology
9.2.3.2. Cardiovascular Diseases
9.2.3.3. Nervous System Diseases
9.2.3.4. Respiratory Disorder
9.2.3.5. Metabolic Diseases
9.2.3.6. Immunologic Diseases
9.2.3.7. Infectious Diseases
9.2.3.8. Others
9.2.4. By End-User
9.2.4.1. Biopharmaceutical Industry
9.2.4.2. Contract Research Organizations (CROs)
9.2.4.3. Academic Institutes and Research Centers
9.2.5. By Country
9.2.5.1. Brazil
9.2.5.2. Argentina
9.2.5.3. Rest of South America
9.2.6. Company Market Share (Top 3-5)
9.2.7. Economic Impact Study on South America AI-Enabled Drug Discovery and Clinical Trials Market

10. Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market Overview

10.1. Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market Size & Forecast, 2016-2027
10.1.1. Demand
10.1.1.1. By Value (USD Million)
10.2. Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market Share & Forecast, 2016-2027
10.2.1. By Component
10.2.1.1. Solutions
10.2.1.2. Services
10.2.2. By Solution
10.2.2.1. Data Aggregation and Analysis
10.2.2.2. Clinical Trials
10.2.2.3. Drug Design
10.2.2.4. Drug Characterization
10.2.2.5. Biomarker Research
10.2.2.6. Others
10.2.3. By Application
10.2.3.1. Oncology
10.2.3.2. Cardiovascular Diseases
10.2.3.3. Nervous System Diseases
10.2.3.4. Respiratory Disorder
10.2.3.5. Metabolic Diseases
10.2.3.6. Immunologic Diseases
10.2.3.7. Infectious Diseases
10.2.3.8. Others
10.2.4. By End-User
10.2.4.1. Biopharmaceutical Industry
10.2.4.2. Contract Research Organizations (CROs)
10.2.4.3. Academic Institutes and Research Centers
10.2.5. By Country
10.2.5.1. Saudi Arabia
10.2.5.2. UAE
10.2.5.3. South Africa
10.2.5.4. Rest of Middle East & Africa
10.2.6. Company Market Share (Top 3-5)
10.2.7. Economic Impact Study on Middle East & Africa AI-Enabled Drug Discovery and Clinical Trials Market

11. Competitor Analysis

11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. Accutar Biotechnology Inc.
11.7.2. AiCure, LLC
11.7.3. Ardigen
11.7.4. Atomwise, Inc
11.7.5. BenevolentAI
11.7.6. Berg LLC
11.7.7. Berkeley Lights, Inc.
11.7.8. BioAge Labs, Inc.
11.7.9. Biovista Inc
11.7.10. C4X Discovery Holdings Plc
11.7.11. Clinithink Ltd
11.7.12. Cloud Pharmaceuticals, Inc.
11.7.13. Cyclica, Inc.
11.7.14. CytoReason,
11.7.15. Symphony Innovation, LLC
11.7.16. Other Prominent Players

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1